Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Michael J. Malecek net worth and biography

Michael Malecek Biography and Net Worth

Insider of Prothena

Mr. Malecek has served as our Chief Legal Officer and Company Secretary since July 2019. Prior to joining Prothena, Mr. Malecek was Vice President, Deputy General Counsel, Intellectual Property & Litigation of Snowflake, Inc., a position he held from 2018 to 2019. Prior to that (between 2010 and 2017), he was a partner of Kaye Scholer and then Arnold & Porter, international law firms that merged in 2016. He served as co-chair of each of the firms’ intellectual property departments, was managing partner of their Silicon Valley offices, and served on the Executive Committee at each firm. Prior to that, Mr. Malecek was a partner with the law firm Dewey & LeBoeuf, was Vice President and Chief Advocacy Counsel with Affymetrix, Inc., was an Assistant U.S. Attorney, and was an attorney with Latham & Watkins. He clerked for Hon. Robert Doumar, Eastern District of Virginia. Mr. Malecek earned his B.A. from Yale University and his J.D. from the University of Virginia.

How old is Michael J. Malecek?: Mr. Malecek is currently 58 years old. There are 7 older executives and no younger executives at Prothena. The oldest executive at Prothena is Ms. Carol D. Karp, Chief Regulatory Officer, who is 71 years old. Learn More on Michael J. Malecek's age.
How do I contact Michael J. Malecek?: The corporate mailing address for Mr. Malecek and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Michael J. Malecek's contact information.
Has Michael J. Malecek been buying or selling shares of Prothena?: Michael J. Malecek has not been actively trading shares of Prothena during the last quarter. Most recently, Michael J. Malecek sold 5,000 shares of the business's stock in a transaction on Wednesday, September 27th. The shares were sold at an average price of $47.38, for a transaction totalling $236,900.00. Learn More on Michael J. Malecek's trading history.
Who are Prothena's active insiders?: Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.
Are insiders buying or selling shares of Prothena?: During the last twelve months, insiders at the biotechnology company sold shares 33 times. They sold a total of 307,333 shares worth more than $20,322,452.52. The most recent insider tranaction occured on January, 24th when CAO Karin L. Walker sold 5,000 shares worth more than $170,000.00. Insiders at Prothena own 28.2% of the company. Learn More about insider trades at Prothena.
Information on this page was last updated on 1/24/2024.

Michael J. Malecek Insider Trading History at Prothena

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/27/2023	Sell	5,000	$47.38	$236,900.00
8/30/2023	Sell	5,000	$55.01	$275,050.00
7/26/2023	Sell	5,000	$62.33	$311,650.00
6/28/2023	Sell	5,000	$69.82	$349,100.00
5/31/2023	Sell	5,000	$64.64	$323,200.00
4/26/2023	Sell	5,000	$53.46	$267,300.00
3/29/2023	Sell	5,000	$49.02	$245,100.00
3/15/2023	Sell	15,000	$48.44	$726,600.00
11/30/2022	Sell	5,000	$62.28	$311,400.00	243
10/27/2022	Sell	20,000	$62.00	$1,240,000.00
11/19/2021	Sell	10,000	$55.00	$550,000.00
10/27/2021	Sell	10,000	$58.52	$585,200.00

Michael J. Malecek Buying and Selling Activity at Prothena

Prothena Company Overview

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $20.79

$20.34

$21.18

50 Day Range

MA: $25.52

$20.56

$30.30

2 Week Range

Now: $20.79

$19.65

$79.65

Volume

96,603 shs

Average Volume

744,893 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

From Priority Gold | Ad